# colorectal cancer - claude-opus-4-8

- Benchmark system: raw
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 66.351
- Final benchmark system: raw; file rank 4/5; original repeat 4; model vendor: Anthropic

---
# Multidimensional Interpretation of Prognostic Transcriptomic Signatures in Colorectal Cancer

## 1. Overall Biological Interpretation

The prognostic transcriptomic profile reveals a metabolically bifurcated tumor biology in colorectal cancer. The protective gene signature is dominated by mitochondrial oxidative metabolism genes (NDUFA9, ATP23, CS, multiple ATP synthase subunits), suggesting that tumors retaining robust mitochondrial function associate with better overall survival. Conversely, the risk-associated signature shows convergence on epithelial-mesenchymal plasticity (ZEB1-AS1, MIR31HG), extracellular matrix remodeling (INHBB, DCBLD2, ITGBL1), and tissue invasion programs (BACE1, ADAMTS18, NT5E). 

This pattern suggests that colorectal tumors with worse prognosis exhibit metabolic reprogramming away from oxidative phosphorylation paired with activation of stromal interaction and invasion machinery. The presence of multiple independently significant mitochondrial genes with HR < 1, alongside mesenchymal and matrix-remodeling genes with HR > 1, indicates these are not isolated molecular events but coordinated biological programs distinguishing prognostic subgroups.

---

## 2. Core Biological Programs

### Program 1: Mitochondrial Oxidative Phosphorylation
- **Direction**: Protective (HR < 1)
- **Major supporting genes**: NDUFA9 (HR=0.69, FDR=0.009), ATP23 (HR=0.69, FDR=0.007), CS (HR=0.75, FDR=0.039), ATP5B (HR=0.75, FDR=0.059), ATP5G1 (HR=0.75, FDR=0.052), TIMM13 (HR=0.75, FDR=0.039), COA3 (HR=0.74, FDR=0.043)
- **Pathway association**: KEGG Oxidative Phosphorylation; Reactome Respiratory Electron Transport; GO:0006119 (oxidative phosphorylation)
- **Biological rationale**: Seven independent genes spanning Complex I (NDUFA9), ATP synthase subunits (ATP5B, ATP5G1), mitochondrial assembly factors (ATP23, COA3), TCA cycle (CS), and mitochondrial protein import (TIMM13) collectively indicate an intact mitochondrial oxidative metabolism program. The consistent protective direction across functionally distinct mitochondrial components argues for genuine biological signal rather than isolated gene effects.
- **Evidence strength**: Strong. Multiple functionally independent genes with concordant protective effects. **Limitations**: The dataset does not distinguish whether this reflects intrinsic tumor metabolism or stromal/immune cell contribution; mitochondrial genes are often constitutively expressed, so observed effects may be diluted relative to true tumor-intrinsic signals.

### Program 2: Epithelial-Mesenchymal Plasticity and Transcriptional Reprogramming
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: ZEB1-AS1 (HR=1.37, FDR=0.009), MIR31HG (HR=1.31, FDR=0.007), NR2F1-AS1 (HR=1.31, FDR=0.036), RUNX1-IT1 (HR=1.31, FDR=0.063)
- **Pathway association**: Hallmark Epithelial-Mesenchymal Transition; GO:0001837 (epithelial to mesenchymal transition)
- **Biological rationale**: ZEB1-AS1 is a long noncoding RNA that stabilizes ZEB1 mRNA, a master EMT transcription factor. MIR31HG hosts microRNAs regulating epithelial identity. The co-occurrence of multiple noncoding RNA regulators of epithelial plasticity, alongside transcriptional modulators (NR2F1-AS1, RUNX1-IT1), suggests coordinated epigenetic and transcriptional reprogramming favoring mesenchymal states.
- **Evidence strength**: Moderate to strong. Multiple independent regulatory RNAs converge on EMT biology. **Limitations**: Long noncoding RNAs and microRNA host genes may reflect passenger effects from broader chromosomal alterations; functional validation of individual lncRNAs in CRC prognosis remains limited. The dataset does not measure protein-level EMT markers (E-cadherin, vimentin), which would strengthen the interpretation.

### Program 3: Extracellular Matrix Remodeling and Stromal Interaction
- **Direction**: Risk-associated (HR > 1)
- **Major supporting genes**: INHBB (HR=1.43, FDR=0.001), DCBLD2 (HR=1.41, FDR=0.009), ITGBL1 (HR=1.30, FDR=0.031), ADAMTS18 (HR=1.26, FDR=0.047), MSLN (HR=1.31, FDR=0.045), NT5E (HR=1.31, FDR=0.039)
- **Pathway association**: Reactome Extracellular Matrix Organization; GO:0030198 (extracellular matrix organization); Hallmark TGF-beta Signaling
- **Biological rationale**: INHBB encodes inhibin beta B, a TGF-beta superfamily ligand promoting fibrosis and tumor-stroma crosstalk. DCBLD2 modulates endothelial and mesenchymal cell responses to growth factors. ITGBL1 and ADAMTS18 directly remodel ECM architecture. MSLN (mesothelin) facilitates tumor cell adhesion and metastasis. NT5E (CD73) generates extracellular adenosine, modulating immune suppression and angiogenesis. These genes collectively represent enhanced tumor-stromal interaction, matrix remodeling, and metastatic niche preparation.
- **Evidence strength**: Strong. Multiple genes with distinct ECM-related functions show concordant risk association. **Limitations**: Some genes (e.g., INHBB, MSLN) may be expressed by stromal or mesothelial cells rather than tumor epithelium; spatial transcriptomics or single-cell validation would clarify cellular origin.

### Program 4: Metabolic Enzyme Repertoire of Differentiated Epithelium
- **Direction**: Protective (HR < 1)
- **Major supporting genes**: ILVBL (HR=0.72, FDR=0.033), GLYCTK (HR=0.71, FDR=0.020), DNPEP (HR=0.73, FDR=0.036), ASL (HR=0.74, FDR=0.036), MCCC2 (HR=0.74, FDR=0.028), OGDHL (HR=0.69, FDR=0.074)
- **Pathway association**: KEGG Valine, Leucine, and Isoleucine Biosynthesis; GO:0006520 (cellular amino acid metabolic process); KEGG Arginine Biosynthesis
- **Biological rationale**: ILVBL (branched-chain amino acid metabolism), MCCC2 (leucine catabolism), ASL (urea cycle/arginine biosynthesis), GLYCTK (glycerate kinase), and DNPEP (aspartyl aminopeptidase) represent metabolic enzymes characteristic of differentiated intestinal epithelium. Their collective protective association suggests that tumors retaining differentiated metabolic programs have better prognosis, consistent with dedifferentiation driving aggressive phenotypes.
- **Evidence strength**: Moderate. Multiple metabolic enzymes show protective effects, but individual effect sizes are modest and some approach FDR thresholds. **Limitations**: These enzymes may reflect general cellular differentiation state rather than specific metabolic dependencies; functional roles in CRC progression are largely unexplored.

### Program 5: Intestinal Differentiation and Tumor Suppressor Transcription
- **Direction**: Protective (HR < 1)
- **Major supporting genes**: CDX2 (HR=0.75, FDR=0.036), CDX1 (HR=0.78, FDR=0.057), MYB (HR=0.77, FDR=0.019), EBF2 (HR=1.27, FDR=0.055, *discordant*)
- **Pathway association**: GO:0030154 (cell differentiation); intestinal epithelial cell differentiation programs
- **Biological rationale**: CDX2 and CDX1 are master transcription factors specifying intestinal epithelial identity and differentiation. Loss of CDX2 in CRC associates with poor differentiation, microsatellite stability, and worse prognosis. MYB regulates colonic epithelial differentiation and crypt homeostasis. The protective association of CDX1/CDX2 reinforces the interpretation that tumors retaining differentiation programs have better outcomes.
- **Evidence strength**: Moderate. CDX2 is well-established as a prognostic marker in CRC, but the current signal relies heavily on two closely related transcription factors. **Limitations**: CDX2 is also used as a diagnostic marker for colorectal
